ICUI:NGS-ICU Medical Inc. (USD)

EQUITY | Medical Instruments & Supplies | Nasdaq Global Select

Last Closing

USD 156.89

Change

0.00 (0.00)%

Market Cap

USD 2.39B

Volume

0.09M

Analyst Target

USD 216.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ICU Medical Inc is engaged in the development, manufacture and sale of medical devices used in infusion therapy, oncology and critical care applications. Its products include needlefree connectors, nanoclave, chemoclock, chemoclave, and among others.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-25 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

+1.81 (+0.34%)

USD 192.19B
COO The Cooper Companies, Inc. Com..

-0.20 (-0.22%)

USD 18.65B
ALGN Align Technology Inc

+2.00 (+0.94%)

USD 17.86B
HOLX Hologic Inc

+0.04 (+0.06%)

USD 17.14B
RGEN Repligen Corporation

-1.17 (-0.80%)

USD 8.36B
MMSI Merit Medical Systems Inc

+0.36 (+0.37%)

USD 6.15B
XRAY Dentsply Sirona Inc

+0.26 (+1.38%)

USD 3.92B
LMAT LeMaitre Vascular Inc

+1.41 (+1.52%)

USD 2.27B
AZTA Azenta Inc

+1.32 (+2.63%)

USD 2.08B
ATRC AtriCure Inc

+0.25 (+0.82%)

USD 1.67B

ETFs Containing ICUI

ISMD Inspire Small/Mid Cap Imp.. 0.00 % 0.62 %

+0.29 (+0.76%)

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 57.30% 81% B- 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.30% 81% B- 88% B+
Trailing 12 Months  
Capital Gain 57.43% 83% B 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 57.43% 83% B 88% B+
Trailing 5 Years  
Capital Gain -15.75% 59% D- 42% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.75% 59% D- 37% F
Average Annual (5 Year Horizon)  
Capital Gain -7.37% 30% F 24% F
Dividend Return -7.37% 28% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.07% 79% B- 65% D
Risk Adjusted Return -26.25% 26% F 21% F
Market Capitalization 2.39B 84% B 86% B+

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 43.80 7% 4%
Price/Book Ratio 1.93 66% 51%
Price / Cash Flow Ratio 23.90 32% 13%
Price/Free Cash Flow Ratio 24.13 24% 16%
Management Effectiveness  
Return on Equity -5.35% 65% 53%
Return on Invested Capital 1.91% 63% 60%
Return on Assets 0.66% 66% 62%
Debt to Equity Ratio 74.30% 11% 31%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector